Logo

Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for th… read more

Healthcare

Biotechnology

17 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.66

Price

+1.88%

$0.16

Market Cap

$743.841m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$34.927m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.57

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$90.958m

$102.432m

Assets

$11.474m

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$37.098m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases